Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis

Cancer Research

Volumn 72, Issue 22, 2012, Pages 5767-5777

  Heinzle, Christine ^a   Gsur, Andrea ^a   Hunjadi, Monika ^a   Erdem, Zeynep ^a   Gauglhofer, Christine ^a   Staẗtner, Stefan ^d   Karner, Josef ^d   Klimpfinger, Martin ^d   Wrba, Friedrich ^b   Reti, Andrea ^d   Hegedus, Balazs ^b,d   Baierl, Andreas ^c   Grasl Kraupp, Bettina ^a   Holzmann, Klaus ^a   Grusch, Michael ^a   Berger, Walter ^a   Marian, Brigitte ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

^d SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 4;

ADULT; AGED; ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CELL MIGRATION; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; FEMALE; FIBROBLAST GROWTH FACTOR RECEPTOR 4 GENE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC RISK; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE; UPREGULATION;

AGED; AGED, 80 AND OVER; ALLELES; CACO-2 CELLS; CELL GROWTH PROCESSES; COLORECTAL NEOPLASMS; FEMALE; GENE KNOCKDOWN TECHNIQUES; GENOTYPE; HCT116 CELLS; HT29 CELLS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4;

EID: 84869221046     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3654     Document Type: Article

References (38)

1. Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 2002;62:840-7.
2. Ma Z, Tsuchiya N, Yuasa T, Inoue T, Kumazawa T, Narita S, et al. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population. Int J Cancer 2008;123:2574-9.
3. Spinola M, Leoni V, Pignatiello C, Conti B, Ravagnani F, Pastorino U, et al. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol 2005;23:7307-11.
4. da Costa Andrade VC, Parise O Jr, Hors CP, de Melo Martins PC, Silva AP, Garicochea B. The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma. Exp Mol Pathol 2007;82:53-7.
5. Streit S, Bange J, Fichtner A, Ihrler S, Issing W, Ullrich A. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 2004;111:213-7.
6. Thussbas C, Nahrig J, Streit S, Bange J, Kriner M, Kates R, et al. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 2006;24:3747-55.
7. Streit S, Mestel DS, Schmidt M, Ullrich A, Berking C. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br J Cancer 2006;94:1879-86.
8. Gordon MA, Gil J, Lu B, Zhang W, Yang D, Yun J, et al. Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics 2006;7:67-88.
9. Spinola M, Leoni VP, Tanuma J, Pettinicchio A, Frattini M, Signoroni S, et al. FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. Oncol Rep 2005;14:415-9.
10. Itoh N. The Fgf families in humans, mice, and zebrafish: their evolutional processes and roles in development, metabolism, and disease. Biol Pharm Bull 2007;30:1819-25.
11. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10:116-29.
12. Kubota Y, Ito K. Chemotactic migration of mesencephalic neural crest cells in the mouse. Dev Dyn 2000;217:170-9.
13. Heinzle C, Sutterluty H, Grusch M, Grasl-Kraupp B, Berger W, Marian B. Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy. Expert Opin Ther Targets 2011;15:829-46.
14. Allerstorfer S, Sonvilla G, Fischer H, Spiegl-Kreinecker S, Gauglhofer C, Setinek U, et al. FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities. Oncogene 2008;27:4180-90.
15. Gauglhofer C, Sagmeister S, Schrottmaier W, Fischer C, Rodgarkia-Dara C, Mohr T, et al. Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology 2011;53:854-64.
16. Metzner T, Held G, Bedeir A, Peter-Vörösmarty B, Ghassemi S, Heinzle C, et al. Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition. J Invest Dermatol 2011;131:2087-95.
17. Sonvilla G, Allerstorfer S, Stattner S, Karner J, Klimpfinger M, Fischer H, et al. FGF18 in Colorectal tumour cells: autocrine and paracrine effects. Carcinogenesis 2008;29:15-24.
18. Roidl A, Berger H-J, Kumar S, Bange J, Knyazev P, Ullrich A. Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 upregulation. Clin Cancer Res 2009;15:2058-66.
19. Stadler CR, Knyazev P, Bange J, Ullrich A. FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression. Cell Signal 2006;18:783-94.
20. Sonvilla G, Allerstorfer S, Heinzle C, Stattner S, Karner J, Klimpfinger M, et al. Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration. Br J Cancer 2010;102:1145-56.
21. Berger W, Setinek U, Hollaus P, Zidek T, Steiner E, Elbling L, et al. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications. J Cancer Res Clin Oncol 2005;131:355-63.
22. Feik E, Baierl A, Hieger B, Führlinger G, Pentz A, Stättner S, et al. Association of IGF1 and IGFBP3 polymorphisms with colorectal polyps and colorectal cancer risk. Cancer Causes Control 2010;21:91-97.
23. Hofer P, Baierl A, Feik E, Führlinger G, Leeb G, Mach K, et al. MNS16A tandem repeats minisatellite of human telomerase gene: a risk factor for colorectal cancer. Carcinogenesis 2011;32:866-71.
24. Gsur A, Bernhart K, Baierl A, Feik E, Führlinger G, Hofer P, et al. No association of XRCC1 polymorphisms Arg194Trp and Arg399Gln with colorectal cancer risk. Cancer Epidemiol 2011;35:e38-e41.
25. Huxley RR, Ansary-Moghaddam A, Clifton P, Czernichow S, Parr CL, Woodward M. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int J Cancer 2009;125:171-80.
26. Jacobs ET, Thompson PA, Martinez ME. Diet, gender, and colorectal neoplasia. J Clin Gastroenterol 2007;41:731-46.
27. Dimidenko E. Sample size determination for logistic regression revisited. Stat Med 2007;26:3385-97.
28. Falvella FS, Frullanti E, Galvan A, Spinola M, Noci S, De Cecco L, et al. FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung. Int J Cancer 2009;124:2880-5.
29. Matakidou A, El Galta R, Rudd MF, Webb EL, Bridle H, Eisen T, et al. Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis. Br J Cancer 2007;96:1904-7.
30. Wang J, Stockton DW, Ittmann M. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 2004;10:6169-78.
31. Ho HK, Pok S, Streit S, Ruhe JE, Hart S, Lim KS, et al. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 2009;50:118-27.
32. Francavilla C, Cattaneo P, Berezin V, Bock E, Ami D, de Marco A, et al. The binding of NCAM to FGFR1 induces a specific cellular response mediated by receptor trafficking. J Cell Biol 2009;187:1101-16.
33. Wang J, Yu W, Cai Y, Ren C, Ittmann MM. Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia 2008;10:847-56.
34. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family: the complete mammalian fgf family. J Biol Chem 2006;281:15694-700.
35. Acevedo VD, Ittmann M, Spencer DM. Paths of FGFR-driven tumorigenesis. Cell Cycle 2009;8:580-8.
36. Knights V, Cook SJ. De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther 2010;125:105-17.
37. Fearon ER, Jones PA. Progressing toward a molecular description of colorectal cancer development. Faseb J 1992;6:2783-90.
38. Muto T, Bussey H, Morson B. The evolution of cancer of the colon and rectum. Cancer 1975;36:2251-70.